Ocuphire Pharma Q4 2022 Earnings Report Earnings HistoryForecast Ocuphire Pharma EPS ResultsActual EPS$1.58Consensus EPS $1.11Beat/MissBeat by +$0.47One Year Ago EPSN/AOcuphire Pharma Revenue ResultsActual Revenue$39.85 millionExpected Revenue$35.00 millionBeat/MissBeat by +$4.85 millionYoY Revenue GrowthN/AOcuphire Pharma Announcement DetailsQuarterQ4 2022Date3/30/2023TimeN/AConference Call ResourcesOCUP Earnings History Ocuphire Pharma Earnings HeadlinesOpus Genetics sets April 30 for 2025 Annual MeetingJanuary 24, 2025 | msn.comOpus Genetics reinstated with a Buy at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 40-year career. During the presentation, Larry reveals a strategy every trader and investor needs to understand. He calls it “Bitcoin Skimming.”January 30, 2025 | Brownstone Research (Ad)Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate UpdateNovember 12, 2024 | markets.businessinsider.comFoundation Fighting Blindness: The RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsOctober 26, 2024 | finanznachrichten.deOcuphire Pharma, Inc. Announces Acquisition of Opus GeneticsOctober 26, 2024 | finanznachrichten.deSee More Ocuphire Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ocuphire Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocuphire Pharma and other key companies, straight to your email. Email Address About Ocuphire PharmaOcuphire Pharma (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.View Ocuphire Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings AbbVie (1/31/2025)AON (1/31/2025)Colgate-Palmolive (1/31/2025)Chevron (1/31/2025)Eaton (1/31/2025)W.W. Grainger (1/31/2025)Novartis (1/31/2025)Snowflake (1/31/2025)Itaú Unibanco (2/2/2025)NXP Semiconductors (2/3/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
